Trial Profile

An Open, Single Arm, Multicenter Phase II Study of Toripalimab Combined With CAV / IE Regimen in Patients With Advanced or Unresectable Bone and Soft Tissue Sarcomas Who Failed Standard Treatment

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 11 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Etoposide (Primary) ; Ifosfamide (Primary) ; Toripalimab (Primary) ; Vincristine (Primary)
Indications Cancer metastases; Chondrosarcoma; Clear cell sarcoma; Dermatofibrosarcoma; Ewing's sarcoma; Gastrointestinal stromal tumours; Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Mesothelioma; Nerve sheath neoplasms; Osteosarcoma; Rhabdomyosarcoma; Soft tissue sarcoma; Solitary-fibrous-tumour; Synovial sarcoma
Focus Therapeutic Use

07 Jan 2024 Planned number of patients changed from 145 to 200.
07 Jan 2024 Planned End Date changed from 30 Jun 2024 to 30 Jun 2026.
07 Jan 2024 Planned primary completion date changed from 30 Jul 2023 to 30 Jan 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com